Exclusive-US FDA Finds Widely Used Asthma Drug Impacts the Brain
6 天之前 · The behavior of montelukast appears similar to other drugs known to have neuropsychiatric effects, such as the antipsychotic risperidone, according to FDA slides reviewed by Reuters.
Exclusive: US FDA finds widely used asthma drug impacts the brain
6 天之前 · Singulair was a blockbuster product for Merck after its launch in 1998, offering relief in a pill as an alternative to an inhaler. ... Reuters, the news and media division of Thomson Reuters, is ...
Popular asthma drug Singulair could be linked to mental health
Singulair, a popular asthma medication, could be linked to severe side effects, including suicide, a study from the FDA found. ... Get all the news you need in your inbox each morning.
Study shows Singulair linked to serious mental health issues
5 天之前 · By 2019, the FDA tallied 82 suicides linked to Singulair and its generic versions reported to its adverse-event database since 1998. At least 31 of those reports involved someone age 19 or younger.
Merck’s Former Asthma Blockbuster Singulair Could Be
6 天之前 · FDA researchers have found new evidence of a molecular link between Merck ’s former blockbuster asthma drug montelukast—which is now marketed by spinoff Organon under the brand name Singulair—with neuropsychiatric problems, according to a Friday report from Reuters.. The regulator’s research, presented Wednesday at the 2024 Annual Meeting of the …
U.S. FDA reportedly finds widely used asthma drug impacts the brain
6 天之前 · The researchers found that the drug, sold under the brand name Singulair, attaches to multiple brain receptors critical to psychiatric functioning.
F.D.A. Warned of Mental Side Effects from Asthma Drug, Singulair…
2024年1月9日 · The agency’s risk-benefit calculus for montelukast has weighed its psychiatric risks against its wide use in treating many patients for asthma, which can be deadly.
Boxed Warning about mental health side effects for Singulair
FDA is requiring a Boxed Warning stating that serious neuropsychiatric events that may include suicidal thoughts or actions have been reported in patients taking montelukast (Singulair).
FDA Requires Stronger Warning About Risk of Neuropsychiatric …
The FDA is requiring a boxed warning for montelukast (sold under the brand name Singulair and in generic form) to strengthen an existing warning about the risk of neuropsychiatric events.
Montelukast will carry 'more prominent warnings’ of …
2024年5月1日 · Montelukast is an oral leukotriene receptor antagonist, indicated as add-on therapy for treatment of mild-to-moderate persistent asthma for patients aged six months and older. Following its safety review, the MHRA said the Yellow Card data indicated a potential lack of awareness of the risk of neuropsychiatric reactions with montelukast among ...